Acquisition, Divestiture, Licensing Arrangement and Equity-Method Investments - Licensing Arrangement (Details) (USD $) In Millions, unless otherwise specified	9 Months Ended						0 Months Ended			1 Months Ended
	Sep. 28, 2014		Sep. 29, 2013		Dec. 31, 2013		Sep. 15, 2014 AstraZeneca, Nexium, Global, Over-the-counter Rights [Member]	Jul. 11, 2014 AstraZeneca, Nexium, Global, Over-the-counter Rights [Member]	Sep. 28, 2014 AstraZeneca, Nexium, Global, Over-the-counter Rights [Member]	Aug. 31, 2014 Collaborative Arrangement, Product [Member] target	Aug. 31, 2014 Collaborative Arrangement, Product [Member] Common Stock [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payments to collaborators										$ 80
Number Of Selected Targets										15
Number of collaboration selected targets										4
Collaborative arrangement, milestone, maximum, value										185
Investment, ownership percentage											10.00%
Long-term investments	18,451	[1]			16,406	[1]				35
Acquisitions of intangible assets	342	[1]	177	[1]			50	200
Contingent consideration milestone payments, maximum possible amount									$ 300

[1] Amounts may not add due to rounding.